Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant and Anastrozole Consolidation in Advanced NSCLC
NCT00932152Phase 2Terminated
- Sponsor
- University of Pittsburgh
- Start
- Sep 2010
- Primary completion
- Jan 2013
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fulvestrant and anastrozole in non-small cell lung cancer (NSCLC) (4 arms), sponsored by University of Pittsburgh. Primary endpoint: Progression-free Survival at 1.5 years. Started Sep 2010; status: terminated.
02
Drugs
fulvestrantanastrozole
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00932152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00932152.